Skip to main content
Premium Trial:

Request an Annual Quote

Movers & Shakers: Oct 23, 2009

Premium

Genome Canada announced last week that Martin Godbout is stepping down from Genome Canada after a decade as its founding president and chief executive officer.

Godbout is returning to the private sector.

In a statement, Genome Canada said Godbout "created a global presence through Genome Canada where Canadian scientists can participate in groundbreaking international research." With his team, he helped secure more than $840 million in government funding, resulting in "the leveraging of close to $1 billion in leading edge genomics and proteomics research" across the country, the non-profit organization added.

Its board has created a transition team made up of board members and management personnel who will oversea the appointment of Godbout's successor and the management and operations of Genome Canada during the interim.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.